Clinical Trial Update: Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating Everolimus in combination with Sorafenib or Sunitinib for metastatic renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Sorafenib (Sorafenib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Andrea Harzstark | Conditions: Locally Metastatic Malignant Neoplasm | Phase 2 | Status: WITHDRAWN